Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Pulse Biosciences, Inc. (PLSE)
|
Add to portfolio |
|
|
|
| Price: |
$21.34
| | Metrics |
| OS: |
54.9
|
M
| |
|
|
| Market cap: |
$1.17
|
B
| |
|
|
|
Net cash:
|
$58.7
|
M
| |
$1.07
|
per share
|
|
EV:
|
$1.11
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.7 | 1.4 | 0.0 | 0.0 | 0.0 | 1.0 | 0.6 | 0.4 |
| Revenue growth | -50.6% | | | | -100.0% | 84.3% | 42.0% | |
| Cost of goods sold | 11.9 | 2.0 | 0.0 | 0.6 | 0.6 | 0.8 | 0.5 | 0.4 |
| Gross profit | -11.2 | -0.6 | 0.0 | -0.6 | -0.6 | 0.2 | 0.1 | 0.0 |
| Gross margin | -1606.3% | -38.8% | | | | 23.6% | 12.0% | 0.0% |
| Selling, general and administrative | | | | 47.4 | 38.0 | | | |
| Sales and marketing | 12.0 | 14.8 | 7.3 | | | | | |
| Research and development | 20.8 | 28.6 | 26.4 | | | 9.6 | 5.5 | 2.2 |
| General and administrative | 14.0 | 19.1 | 16.3 | | | 15.5 | 3.4 | 1.6 |
| EBITA | -57.4 | -62.3 | -49.3 | -45.3 | 0.7 | -24.9 | -8.9 | -3.8 |
| EBITA margin | -8198.9% | -4396.9% | | | | -2378.4% | -1558.6% | -950.5% |
| Amortization of intangibles | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
| EBIT | -58.1 | -63.0 | -50.0 | -46.0 | 0.0 | -25.6 | -9.5 | -4.5 |
| EBIT margin | -8293.9% | -4443.9% | | | | -2441.9% | -1675.7% | -1117.0% |
| Pre-tax income | -58.5 | -63.7 | -49.9 | -47.0 | -37.5 | -25.6 | -9.5 | -4.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.7 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 37.1% |
| Net income | -58.5 | -63.7 | -49.9 | -47.0 | -37.5 | -25.6 | -9.5 | -2.8 |
| Net margin | -8357.9% | -4489.4% | | | | -2441.9% | -1675.7% | -702.8% |
| |
| Diluted EPS | ($1.72) | ($2.28) | ($2.14) | ($2.26) | ($2.20) | ($1.73) | ($0.86) | ($0.37) |
| Shares outstanding (diluted) | 33.9 | 28.0 | 23.2 | 20.7 | 17.1 | 14.8 | 11.0 | 7.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|